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ABSTRACT 
 
     Acute Radiation- induced Skin reaction (ARISR) is a common side effect in the majority of patients 
receiving radiotherapy. ARISR is often characterized by swelling, redness, pigmentation, dry and moist 
desquamation, edema, ulceration, bleeding and necrosis of the Skin. This study was carried out to 
evaluate prevalence and severity of ARISR in patients with head and neck cancer undergoing 
radiotherapy and determining skin dose–response relationship. From December 2014 to September 2015, 
we evaluated 88 patients with head and neck cancer. The acute skin toxicity was scored based on RTOG 
toxicity criteria. Analysis of data using statistical software SPSS (version20) and ANOVA or chi- square 
test was done, with P   0.05 considered as significant. 98.86% of patients experienced dermatitis, but 
were mild in most cases.There was no significant differences in age, sex, stage, and field size between 
patients with dermatitis. 
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INTRODUCTION 
     The incidence of cancer in different 
communities is increasing as cancer is the 
second leading cause of death in developed 
countries [1]. Head and neck cancers constitute 
two to five percent of these malignancies that 
represent a rather heterogeneous group of 
neoplasm originating from the oral cavity, 
oropharynx, hypo pharynx, larynx and other 
areas [2]. Radiotherapy is one of the main 
modality in the management of cancer 
treatment, along with chemotherapy and 
surgery. The goal of Radiotherapy is to provide 
maximum damage to tumor with the minimal 
side effect [3], and yet, it associated with a 
number of short-term and long-term side- 
effects [4].One of the most common side effects 
of radiation is acute skin reaction, affecting up 
to 95% of people receiving radiation treatment 
for their cancer [5], and sice skin is usually the 
first site of entry in radiation treatment, variable 
degrees of skin reaction can occur. The 
reactions are the result of radiation treatment 
disrupting the normal process of cell division 
and regeneration in the basal cell layer of the 
skin, resulting in cell damage or cell death [6]. 
The damage can be a result of several processes, 
including a reduction of endothelial cell 
changes, inflammation, and epidermal cell death 
[7]. Acute radiation- induced skin reactions are 
often characterized by swelling, redness, 
pigmentation, dry and moist desquamation, 
fibrosis, and ulceration of the skin; signs and 
symptoms are expressed as pain, warmth, 
burning and itching of the skin [8].Erythema is 
defined as the redness caused by flushing of the 
skin due to dilatation of the blood capillaries in 
the dermis [9]; dry desquamation is the 
shedding of the outer layers of the skin thins 
because the new cells reproduce faster than the 
old cells are shed so the skin begins to weep as 
a result of loss of integrity of the epithelial 
barrier and decrease in pressure exerted by 
plasma proteins on the capillary wall [9]. The 
cumulative effect of further doses of 
radiotherapy can then cause the skin to break 
down edematous with exudates leading to moist 
desquamation. Skin necrosis is rarely seen 
 




primarily due to the advanced techniques used 
in the delivery of radiotherapy .Skin reactions 
related to radiation therapy usually manifest 1-4 
weeks after radiotherapy onset, persist for the 
duration of radiation therapy, and may require 
4-6 weeks to heal after completion of therapy 
[10], with the exception that the area may still 
look hyper pigmented (darker) [11]. 
Radiation- induced skin reaction have an impact 
on the level of pain/ discomfort experienced and 
the quality of life of those who undergo 
radiation treatment [12], and may even require 
changes to person's radiation schedule (if 
severe) [9]. In some cases, complex surgical 
reconstruction of damage skin may be required 
[13]. 
 
MATERIALS AND METHODS 
     This study was done at the radiation 
oncology department of Tohid hospital at 
Sanandaj, Iran. The department is equipped 
with a linear (Waxttan baxer Elekta synergy 
plat, Elekta) and 3D-conformal planning 
systems (Isogray from Dosisoft Company). We 
analyzed 88 patients with head and neck cancer 
that had been referred to our department from 
1
st
 of December 2014 to 30
th
 of September 
2015. All patients provided their written 
informed consent. There were no restrictions on 
age and gender of the patients. A pre-coded 
questionnaire was developed for this study, 
which included simple demographic details viz. 
age, gender, information regarding the 
malignancy i.e. tumor morphology and staging, 
information regarding the treatment i.e. 
radiotherapy alone or combined with 
chemotherapy, total tumor dose delivered to the 
patients, dose per fraction, treatment time, field 
size, skin dose at 2mm depth  and complication. 
Complications were categorized into radiation  
therapy (RT) symptoms with  skin (dermatitis). 
The cancers were staged using the UICC/AYCC 
TNM system [14]. Radiotherapy for all patients 
was planned using the Isogray three 
dimensional treatment planning system 
(Dosisoft medical system version 4.1) to 
facilitate treatment planning. CT of the head 
and neck was obtained for each patient with 
thermoplastic immobilization shell. The clinical 
target volume (CTV) was defined as the entire 
tumor invasion subsides. The planning target 
volume (PTV) was obtained by adding a 10 mm 
margin to the CTV and an additional 15 mm 
margin from the skin.  Prophylactic neck lymph 
node area irradiation was performed. Radiation 
fields were customized as appropriate by a 
Multileaf collimator. All sites irradiated with 6- 
10 MV photon beams. The daily dose was 1.8 
or 2Gy per fraction up to total dose, 5 days per 
week. As a standard practice, all cases were 
treated with acceptable tolerance doses to the 
organs at risk, namely spinal cord, brainstem 
and optic chiasma. Skin dose at a depth of 2 mm 
was calculated using the three dimensional 
treatment planning system and collapsed cone 
algorithm from point kernel section. For each 
patient contour with 7 cm
3
 volume size in the 
treatment field was drawn. In computing 
software, voxels size was 2 mm
3
. Chemotherapy 
was done with an intravenous loading dose of 
cetuximab (400-600 mg/m
2
) or Cisplatin (50 
mg/ m
2
) during radiotherapy. The median cycle 
of chemotherapy was six cycle. 
Acute dermatitis were assessed weekly during 
treatment up to 13 weeks from beginning of 
radiotherapy and graded according to the 
radiation therapy oncology group/ European 
organization for research and treatment of 
cancer criteria (RTOG/EORTC) [15]. 
 
 
Table 1. RTOG acute radiation scoring criteria-skin 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
No change 
Over baseline 
Follicular, faint or dull 
erythema; epilation; dry 
desquamation; decreased 
sweating 





desquamation other than 




RTOG (Radiation Therapy Oncology Group)  
and EORTC (European Organization for 
Research and Treatment of Cancer). All 
analyses were performed using SPSS software 
(version 20) to investigate the relationship 
between skin reaction in different grades of 
RTOG/ EORTC with variables, ANOVA and 
Chi-square test was used as the main tool. 
Turkey's post hoc test was used to study the 
difference in the incidence of skin reactions in 
various grades. P value of 0.05 or less was 
considered statistically significant. 
 





Between December 2014 and September 2015, 
88 patients with head and neck cancer received  
RT in Tohid hospital at Sanandaj, Iran.  
Table 2 shows patient characteristics. 
Table2. Patient and tumor characteristics (n=88)  
 
 
The median age was 58 years old (range 18-85). 
60 (68%) patients were male and 28 (31%) were 
females. Radiation doses ranging were from 13 
to 75 GY (median = 58 GY), skin dose at 2 mm 
depth ranging were from 11 to 66 GY (median= 
44 GY).The dose per fraction was 1.8 GY in 46 
(52%) patients, 2 GY in 32 (36%) patient, and 
10 (11%) were treated with both fraction sizes, 
and treatment time ranged from 21 to 64 days, 
with a median of 42 days. Concurrent 
chemotherapy with radiotherapy was done for 
40 (45%) patients, surgery was performed in 35 





), primary tumor site were 
the larynx in 26, thyroid in 9, parotid in 7, oral 
cavity in 7, nasopharynx in 4, maxilla in 4, 
hypopharynx in 7, mandible in 7, neck 
esophagus in 5, neck in 12 and unknown origin 
of region in 5 patients. 64 (73%) patients had 
squamous cell carcinoma (SCC), 10(11 %) had 
sarcoma and 14 (15%) had lymphoma. 14 
(15%) of the patients were stage I, 25(28%) 
were stage II, 47(53%) were stag III and 2 (2%) 
were stage IV.  
Considering the fact that the average length of 
treatment time is six week (42 day), we 
analyzed prevalence and severity of acute 
radiation- induced skin reactions in 6 and 13 
weeks as acute complications during and after 
treatment with confounding factors like age, 
gender, tumor stage, treatment method, field 
size, total dose, skin dose at 2 mm depth, dose 
per fraction and treatment time. Radiotherapy 
was completed in all patients. 98.86% of 
patients experienced dermatitis (RTOG grades 
1-4) (tables 3, 4). 
 
 
Variable Number (%) 
Age (years- median) 18-85 (58)  
Gender   
Male 60 (68.2) 
Female 28 (31.8) 
Primary tumor site   
Larynx 26 (21.3) 
Thyroid 9 (10.4) 
Parotid 7 (7.9) 
Neck 12 (13.7) 
Oral cavity 7 (7.9) 
Nasopharynx 4 (4.6) 
maxilla 4 (4.6) 
Hypo pharynx 2 (2.3) 
Mandible 7 (7.9) 
Cervical esophagus 5 (5.7) 
Unknown origin of region 5 (5.7) 
Stage   
I 14 (15.9) 
II 25 (28.4) 
III 47 (53.4) 
IV 2 (2.3) 
Pathology   
Squamous cell carcinoma 64 (72.7) 
Sarcoma 10 (11.4) 
Lymphoma 14 (15.9) 
Concurrent  chemotherapy   
Yes 40 (45.5) 
No 48 (54.5) 
Surgery   
Yes 35 (39.8) 
No 53 (60.2) 
 




Table 3. Acute adverse effects during treatment 
Grade 0 1 2 3 4 
Dermatitis 1 44 38 4 1 
RTOG/ EORTC 
Table 4. Acute adverse effects after treatment 
RTOG/ EORTC 
 
Dermatitis grade 1 and 2 were the most 
common acute toxicity while one patient had 
grade 4 toxicity. We observed that the severity 
of ARISR is higher with increasing total dose, 
skin dose at 2mm depth, and dose per fraction 
and treatment time. Furthermore, we analyzed 
the severity of ARISR with tumor stage and 
treatment method. We observed that the severity 
of ARISR is higher in larger T-stage. In patient 
that radiotherapy was done with chemotherapy,  
complications were more severe. Regarding  
 
sex, we observed that the incidence of 
complications is higher in men than in women 
and is less severe. However, there were no 
significant difference in age, gender, tumor 
stage, field size, total dose and skin dose at 
2mm depth between patient with complication 
(p>0.05), but dose per fraction (during 
treatment) and treatment time (after treatment) 
had significant effect on complication (p<0.05) 
( tables 5-8).  
 
 
Table 5. Association of clinical factors and the risk of acute skin reaction during treatment 
Variable Grade0 Grade1 Grade2 Grde3 Grade4 X2 P-value 
Age >50 0(0) 11(47.8) 12(52.2) 0(0) 0(0) 8.98 0.342 
50-70 0(0) 24(51.1) 18(38.3) 4(8.5) 1(2.1) 
>70 1(5.6) 9(50) 8(44.4) 0(0) 0(0) 
Gender Male 0(0) 32(53.3) 27(45) 1(1.7) 0(0) 8.28 0.082 
Female 1(3.6) 12(42.9) 11(39.3) 3(10.7) 1(3.6) 
Stage I 1(7.1) 8(57.1) 5(35.7) 0(0) 0(0) 11.42 0.0494 
II 0(0) 14(56) 9(36) 2(8) 0(0) 
III 0(0) 20(42.6) 24(51.1) 2(4.3) 1(2.1) 
IV 0(0) 2(100) 0(0) 0(0) 0(0) 
Concurrent 
chemotherapy 
Yes 0(0) 20(50) 19(47.5) 0(0) 0(0) 5.683 0.224 
 No 1(2.1) 24(50) 19(39.6) 4(8.3) 0(0) 
Dose per fraction 1.8 GY 1(2.2) 24(52.2) 21(45.7) 0(0) 0(0) 9.152 0.01 
2 GY 0(0) 16(50) 12(37.5) 4(12.5) 0(0) 
Both 0(0) 4(40) 5(50) 0(0) 1(10) 
 
Abbreviations: RTOG = Radiation Therapy 
oncology Group; EORTC=European 
organization for Research and Treatment of 




Table 6. Association of clinical factors and the risk of acute skin reaction during treatment 












Grade0 1 60.13 0 0 0.599 
Grade1 44 86.81 68.73 65.91-107.7 
Grade2 38 68.7 37.15 56.49-80.91 
Grade3 4 67.27 20.63 34.49-100.11 
Grade4 1 45.1 0 0 
Total dose Grade0 1 45 0 0 0.734 
Grade1 44 57.48 10.78 54.2-60.76 
Grade2 38 58.83 11.9 54.92-62.75 
Grade3 4 59 6.63 48.44-69.55 
Grade4 1 64 0 0 
Skin dose at 
2mm depth 
Grade0 1 25.83 0 0 0.413 
Grade1 44 45.04 12.99 41.08-48.99 
Grade2 38 44.61 11.7 40.71-48.51 
Grade3 4 47.68 7.82 35.23-60.13 
Grade 0 1 2 3 4 
Dermatitis 24 61 3 0 0 
 




Grade4 1 59.18 0 0 
OTT(day) Grade0 1 31 0 0 0.694 
Grade1 44 42 10.07 38.93-45.06 
Grade2 38 43.63 9.35 40.55-46.7 
Grade3 4 44.5 8.22 31.41-57.58 
Grade4 1 45 0 0 
 
 
Abbreviations: RTOG = Radiation Therapy 
oncology Group; EORTC=European 
organization for Research and Treatment of 
Cancer; GY= Gray; OTT=Overall Treatment 
time 
 
Table 7. Association of clinical factors and the risk of acute skin reactions after treatment 
Variable Grade0 Grade1 Grade2 X2 P-value 
Age <50 6(26.1) 17(73.9) 0(0) 2.8 0.592 
50-70 13(27.7) 3(66) 3(6.4) 
>70 5(27.8) 13(72.2) 0(0) 
Gender Male 16(26/7) 43(71.7) 1(1.7) 1.85 0.396 
Female 8(28.6) 18(64.3) 2(7.1) 
Stage I 5(35.7) 9(64.3) 0(0) 7.85 0.249 
II 10(40) 13(52) 2(8) 
III 9(19.1) 37(78.7) 1(2.1) 
IV 0(0) 2(100) 0(0) 
Concurrent 
chemotherapy 
Yes 6(15) 34(85) 0(0) 9.152 0.01 
No 18(37.5) 27(56.2) 3(6.2) 
Dose per fraction 1.8 GY 14(30.4) 32(69.6) 0(0) 7.35 0.118 
2 GY 9(28.1) 20(62.5) 3(9.4) 
Both 1(10) 9(90) 0(0) 
Abbreviations: RTOG = Radiation Therapy 
oncology Group; EORTC=European 
organization for Research and Treatment of 
Cancer; GY= Gray; OTT=Overall Treatment 
time 
  
Table8. Association of clinical factors and the risk of acute skin reactions after   treatment 
Variable Skin reaction 
(RTOG-Grade) 
Number Median Std. deviation 95%Confidence Interval P-value 
Field size(cm2) Grade0 24 85.82 63.91 58.83-112.80 0.658 
Grade1 61 74.54 52.63 61.06-88.02 
Grade2 3 66.03 25.09 3.69-128.37 
Total dose Grade0 24 54.4 10.76 46.85-58.94 0.149 
Grade1 61 59.32 11.16 56.46-62.18 
Grade2 3 62 3.46 53.39-70.6 
Skin dose at 
2mm depth 
Grade0 24 43.25 9.61 39.19-47.31 0.611 
Grade1 61 45.34 13.38 41.88-48.80 
Grade2 3 49.87 7.93 30.15-69.59 
OTT(day) Grade0 24 37.62 6.68 33.53-41.71 0.007 
Grade1 61 44.4 9/02 42.18-46.8 
Grade2 3 47.66 6.42 31.69-13.63 
Abbreviations: RTOG = Radiation Therapy 
oncology Group; EORTC=European 
organization for Research and Treatment of 





     
     Radiation skin reactions are an inevitable 
consequence of radiotherapy. Although the 
widespread use of linear accelerators has 
reduced the severity of skin reactions through 
more sophisticated skin-sparing techniques, the 
increased use of concomitant chemotherapy and 
high-dose radiotherapy means that skin 
reactions can still be a significant problem for 
patients. A survey carried out in the early 1990s 
by Barkham A reported that more than 80% of 
 




UK radiotherapy departments frequently face 
skin reactions, although these were not usually 
severe [16]. The results of the present study 
show that Grade 3 and 4 acute radiation 
dermatitis occurred in 5% of patients. The 
adverse event profile in our study was mostly in 
line with those originally reported by Bonner et 
al [17]. In general areas of body that contain 
skin fold are more likely to be affected by 
radiation such as under the breast, axilla and 
H&N, because of a phenomenon called the 
“bolus effect”. These areas are more likely to 
receive a higher dose of radiation and more 
prone to bacterial contamination [18].This study 
was performed to analyze the influence of 
confounding factors on the development of 
acute radiation-induced skin toxicity, and also 
to determine skin dose at 2mm depth -response 
that can be used as a dosimeter in clinic.  We 
observed that in patients with 50-70 years of 
age, skin toxicity was higher than patients in>70 
years old group. Canhua X, et al. found that 
increased age resulted in an impaired ability to 
heal [19], and alternative explanation for our 
finding is that the older patients (>70 years old) 
were less likely to have received chemotherapy 
and that might have affected the degree of skin 
reactions they experienced. Chan et al. [20] 
reported that they observed a 61% rate of grade 
III to IV radiation dermatitis among HNSCC 
patients treated with concurrent radiotherapy 
and cetuximab.O’Rourke ME et al, A etal, and 
Suga T et al found that chemo radiation regime 
increases the severity of skin reactions. The 
main principle of chemotherapy is that two 
treatments work synergistically so as to improve 
overall response, but radiation side effects tend 
to be exacerbated by the addition of 
chemotherapy; our data support that finding.  In 
fact the adverse effect complications were in 
line with those expected with the concomitant 
administration of cetuximab and radiotherapy 
[21-22-23]. In terms of total dose and skin dose, 
Archambeau et al found that basal cell loss 
began once the radiation dose reached 20-25 
Gy, and maximum depletion occurred at a dose 
of 50Gy, and by the time higher doses of up to 
60 Gy had been absorbed, repopulation of basal 
cells had occurred, so that levels were similar to  
those existing prior to radiotherapy [24]. Giro et 
al observed that a higher total dose and skin 
dose were significantly correlated with the 
development of high grade  dermatitis [25]. 
Corresponding to those studies, we found that 
higher total dose and skin dose at 2mm depth 
had a positive trend to development of toxicity. 
In fact in our study ARISR were potentiated at 
the end of treatment, Grade 1 and 2 
complications occurred at a median skin dose at 
2mm depth of 44-45 Gy and Grade 3and 4 
complications occurred at a median dose of 47-
60 Gy. Mendenhall et al reported that higher 
daily fraction doses resulted in higher local 
control rates without a significant increase in 
acute adverse effect [26]. Chan et al found that 
a smaller daily radiation dose decreases the risk 
of radio dermatitis [20]. We observed that the 
occurrence of ARISR was lower among patients 
treated with smaller daily fraction dose. Overall 
treatment time was thought to be one of the 
keys for tumor control. Our study showed an 
association between longer treatment time and 
higher rate of ARISR, because longer treatment 
time results in higher total dose, hence, more 
complications [26]. Lee IJ et al reported that 
patients with larger tumors had more 
complications, probably experienced more 
trauma to surrounding tissue during surgery, 
and thus had a reduced potential for wound 
healing.  Our finding support the forementioned 
theory, as larger T-stages showed a positive 
trend to development of higher acute toxicity 
[27]. Corresponding to Alvarengea LM et al. 
studies [28], superiority of males was evident as 
68/2% of patients were male, and they also 
experienced more complications. In contrast to 
our data, Marie k et al found no correlation 
between sex and acute radio dermatitis [29]. As 
the policies in radiation departments head and 
neck tumor treatment with different radiation 
field such as anterior, posterior, lateral and 
tangential, and target volume (PTV) shrinkage 
related to the clinical target volume (PTV) in 
the proximity of the skin, we determine the 
severity of skin toxicity and smallest field size 
which had a longer exposure time,. Contrary to 
Alvarengea LM et al, we found higher rates of 
radiation dermatitis in smaller field size [28]. 
 
CONCLUSION 
     A number of treatment and patient related 
factors are identified that can modify the risk 
for the development of acute radiation- induced 
skin reactions. In this study, we analyzed the 
 




effect of some of them.  Our results indicated 
that the incidence rate of ARISR in head and 
neck cancer patients undergoing radiotherapy or 
chemo radiation were high. They should be kept 
in mind in order to increase the safety of the 
treatment. Moreover, we proposed that  a mean 
dose under 25 GY delivered to the 2mm depth 
of skin are  safe, through doses of  45-47 GY 
should be given with caution and extra 
monitoring; doses greater than 50 GY are 
dangerous and likely to produce grade 4 acute 
radiation dermatitis .   
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